Zantac (Ranitidine)
Zantac/ Ranitidine
If you or a loved one have taken Zantac (Ranitidine) and been diagnosed with cancer, you may be entitled to compensation.
Zantac (Ranitidine) is a popular antacid medication that has been on the market since the 1980’s. It belongs to a class of drugs called histamine H2-receptor antagonists, or H2 blockers, which decrease the amount of acid produced by the stomach. Zantac (Ranitidine) is available over the counter and by prescription.
Increased risk of cancer
Unfortunately, studies have demonstrated a link between the probable human carcinogen N-nitrosodimethylamine (NDMA) in Zantac (Ranitidine) and cancer. Similar types of NDMA exposure have been linked to various cancers, including:
- Stomach
- Small Intestine
- Colorectal
- Esophageal
- Liver
- Bladder
- Prostate
- Pancreatic
- Leukemia
- Non-Hodgkin’s Lymphoma
- Multiple Myeloma
- Kidney
In September 2019, the FDA issued a public safety warning about possible cancer risks from Zantac (Ranitidine). There has been a Zantac (Ranitidine) recall and has been pulled from the shelves across the country.
We are here to help
If you or someone you care about have taken Zantac (Ranitidine) and suffered one of these cancer injuries, please contact Brown and Crouppen today for a free and confidential case evaluation. We can help you make informed decisions about your legal rights, so please call us Toll-Free: 877-448-5415 for your free legal consultation or save time with our online Contact Form.
